[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":637},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,98,0,25,[9,41,71,100,127,153,175,200,227,250,272,296,319,340,367,387,411,436,457,481,511,537,558,589,617],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100478322","ablative-radiotherapy-to-restrain-every-metastasis-safely-treatable-arrest-2-a-randomized-phase-iiiii-trial-100478322",false,"NCT05508464","Ablative Radiotherapy to Restrain Every Metastasis Safely Treatable (ARREST-2): A Randomized Phase II\u002FIII Trial","ARREST2","Inclusion Criteria:\n\n* Age 18 or older\n* willing and able to provide informed consent\n* ECOG performance status 0-2\n* Life expectancy \\> or equal to 6 months\n* Histologically confirmed malignancy with evidence of metastatic disease on imaging\n* All sites of disease can be safely treated on a preliminary radiation plan\n* \\> or equal to 11 metastases (the primary tumor does not have to be controlled and can be included as a target if it can feasibly and safely be treated with SABR. If the primary tumor is treated, a minimum of 12 targets are required0 at least 11 metastases are required in addition to the primary tumor.)\n* Investigations required within 12 weeks of enrollment:\n* Brain: MRI is required for all patients with known untreated or previously treated brain metastases. MRI is strongly recommended for all tumor sites with a propensity to develop brian metastases.\n* Body: 18-FDG PET\u002FCT imaging is recommended, except for tumors where FDG uptake is not expected (e.g. prostate, renal cell carcinoma). PSMA-PET or choline-PET is recommended for prostate cancer. In situations where a PET scan is unavailable, or for tumors that do not take up radiotracer, a CT neck\u002Fchest\u002Fabdomen\u002Fpelvis and bone scan are required.\n* Liver: For patients with liver metastases, a diagnostic or simulation MRI is required to confirm the total number of metastases.\n* No plans for systemic therapy (i.e. chemotherapy, targeted agent, immunotherapy) for 3 months from the time of enrolment. Reasons may include: a break from systemic therapy is desired by the patient and medical oncologist, the patient declines next line of systemic therapy, or no further systemic therapy options are available. Exceptions include hormone therapy for breast cancer or prostate cancer, which may be continued.\n* SABR or palliative radiotherapy should commence no later than 2 weeks after randomization.\n* For patients with brain metastases that are going to be treated regardless of the study arm, there must be additional extracranial disease present that will be treated with SABR on Arm 2 and not treated with SABR on Arm 1.\n\nExclusion Criteria:\n\n* Serious medical comorbidities precluding radiotherapy. These include interstitial lung disease in patients requiring thoracic radiation, Chrohn's disease in patients where the GI tract will receive radiotherapy, ulcerative colitis where the bowel will receive radiotherapy and connective tissue disorders such as lupus or scleroderma.\n* For patients with liver metastases, moderate\u002Fsevere liver dysfunction (Child-Pugh B or C)\n* Substantial overlap with a previously treated radiation volume. Prior radiotherapy is allowed, as long as the composite plan meets dose constraints herein. For patients treated with radiation previously, biologically effective dose calculations should be used to equate previous doses to the tolerance doses listed in Appendix 1. All such cases must be discussed with the study PI.\n* Inability to treat all sites of disease. Any brain metastasis \\>3 cm in size or a total volume of brain metastases greater than 30 cc.\n* Solitary or dominant brian metastasis requiring surgical decompression.\n* Radiologic evidence of spinal cord compression.\n* Disseminated disease, including leptomeningeal metastases, peritoneal metastases\u002Fcarcinomatosis, malignant pleural effusion, and lymphangitis carcinomatosis.\n* Pregnant or lactating women.","ALL","18 Years",{"count":20,"type":21},138,"ESTIMATED","INTERVENTIONAL",[24],"NA","This is a phase II\u002FIII international multicentre randomized trial. Patients will be randomized in a 1:2 ratio between the standard of care (Arm 1) and SABR (Arm 2) to all sites of disease. The study will start as a phase II trial with an opportunity to convert to a phase III trial. The objective of this trial is to determine the impact of SABR on overall survival, progression-free survival, quality of life, and toxicity in patients with polymetastatic disease.",[27],"Metastatic Cancer","RECRUITING","2026-06-26",{"date":31,"type":32},"2026-06-29","ACTUAL",{"date":34,"type":32},"2023-10-16",{"date":36,"type":21},"2034-01-01",{"name":38,"class":39},"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","OTHER",3,{"id":42,"slug":43,"hasResults":12,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":22,"phases":50,"briefSummary":51,"conditions":52,"keywords":54,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":4},"100641222","perforated-appendicitis-and-postoperative-antibiotics-pilot-trial-100641222","NCT07656636","Perforated Appendicitis and Postoperative Antibiotics Pilot Trial","PAPA Pilot","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Scheduled to undergo an open or laparoscopic appendectomy\n* Complicated appendicitis confirmed intra-operatively (AAST Appendicitis Grade III or IV)\n\nExclusion Criteria:\n\n* Patients demonstrating signs of septic shock for whom the omission of systemic antibiotics is contraindicated\n* Patients with positive blood cultures for whom antibiotics are required for treatment of the bacteremia\n* Immunosuppressed patients\n* AAST Appendicitis Grade V",{"count":49,"type":21},100,[24],"The goal of this clinical trial is to learn if not giving antibiotics is as effective as giving antibiotics after surgery for patients who have surgery for a perforated (burst) appendix. This pilot study will also help determine whether a larger, multi-centre study can be successfully conducted. The main questions it aims to answer are:\n\n* Do patients who do not receive antibiotics after surgery have similar rates of infection after surgery as patients who do?\n* Is it feasible to enroll and randomize patients and collect complete health data for a larger multi-centre study?\n\nResearchers will compare patients who do not receive antibiotics after surgery to patients who do to see whether avoiding antibiotics is as effective as using antibiotics for preventing infections after surgery.\n\nParticipants will:\n\n* Be randomly assigned to either receive or not receive antibiotics after surgery for their perforated (burst) appendix.\n* Be contacted 30 and 90 days after surgery to check for infections and other health outcomes.",[53],"Perforated Appendicitis",[55,56,57,58,59,60,61],"Perforated appendicitis","Complicated appendicitis","Postoperative antibiotics","Randomized controlled trial","Pilot trial","Acute care surgery","Emergency general surgery","NOT_YET_RECRUITING","2026-06-15",{"date":65,"type":32},"2026-06-18",{"date":67,"type":21},"2026-08-01",{"date":69,"type":21},"2027-11-01",{"name":38,"class":39},{"id":72,"slug":73,"hasResults":12,"nctId":74,"briefTitle":75,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":12,"sex":77,"minAge":18,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":22,"phases":80,"briefSummary":82,"conditions":83,"keywords":86,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},"100641406","phase-1-a-phase-i-evaluation-of-the-safety-and-tolerability-of-pirfenidone-in-idiopathic-subglottic-stenosis-100641406","NCT07654517","A Phase I Evaluation of the Safety and Tolerability of Pirfenidone in Idiopathic Subglottic Stenosis","Inclusion Criteria:\n\n* Adults 18-65 years of age\n* Confirmed diagnosis of idiopathic subglottic stenosis (iSGS)\n* History of at least 2 endoscopic dilations within the past 12 months or -Receiving regular intralesional steroid injections as part of iSGS management (every 3 months)\n* Clinically stable at enrollment (no acute infection or active inflammation)\n* Adequate liver and renal function on screening laboratory tests\n* Willing and able to comply with study procedures, visits, and follow-up\n* Ability to provide written informed consent\n* For participants of childbearing potential: negative pregnancy test and agreement to use effective contraception during treatment and for the protocol-specified period after the last dose\n\nExclusion Criteria:\n\n* Subglottic stenosis due to another identifiable cause (e.g., intubation, granulomatosis with polyangiitis, malignancy)\n* Known hypersensitivity or allergic reaction to pirfenidone or any component of its formulation\n* Severe hepatic impairment or active liver disease (AST or ALT above the upper limit of normal)\n* Severe renal impairment or requirement for dialysis\n* Concurrent use of fluvoxamine\n* Use of high-dose ciprofloxacin or other strong CYP1A2 inhibitors where dose adjustment is not feasible\n* Current smoking or unwillingness to abstain from smoking during treatment\n* Pregnant or breastfeeding individuals\n* Clinically significant comorbid illness that could increase risk or confound results (e.g., advanced cardiac, pulmonary, or autoimmune disease)\n* History of photosensitivity disorders or inability to adhere to sun protection precautions\n* Participation in another investigational clinical trial within the previous 30 days\n* Any condition that, in the investigator's judgment, would interfere with safety monitoring, adherence, or study assessments","FEMALE",{"count":79,"type":21},40,[81],"PHASE1","Idiopathic subglottic stenosis (iSGS) is a rare condition where scar tissue forms just below the vocal cords and in the upper windpipe, making the airway narrow. People with iSGS often feel short of breath, hear noisy breathing, and notice changes in their voice. Many need repeated operations and steroid injections to open the airway, but the narrowing usually comes back, so these treatments are not a cure.\n\nRecent research from a Canadian iSGS registry and biobank has shown that this disease is driven by overactive scarring pathways, similar to those seen in idiopathic pulmonary fibrosis (IPF), a serious lung disease. Pirfenidone is an oral medication already approved for IPF that works by slowing down the cells and signals that cause scarring. Because the same scarring pathways appear to be active in iSGS, pirfenidone may be able to slow or reduce the build-up of scar tissue in the airway.\n\nIn this study, adults with iSGS will be randomly assigned (like flipping a coin) to receive either pirfenidone or a placebo (a look-alike pill with no active drug) for 52 weeks, in addition to their usual intralesional steroid injections. The pirfenidone dose will be increased gradually over the first two weeks up to a regular dose taken three times a day with food, which is the same schedule used in patients with IPF. Participants and their doctors will not know which treatment they are getting until the end of the study, unless this needs to be revealed for safety reasons.\n\nThe main goal of this trial is to see how safe pirfenidone is for people with iSGS and how well they can tolerate taking it for one year. The study team will watch closely for side effects such as stomach upset, skin rash or sensitivity to sunlight, tiredness, and changes in liver blood tests. They will also look for early signs that pirfenidone may help, such as longer time until the next airway dilation, better breathing tests, and improvements in breathlessness and voice-related quality of life scores.\n\nParticipants will be followed for a total of up to two years, including one year on study medication and one year of follow-up. This study may not directly help every person who takes part, but the results will provide important information about whether pirfenidone is safe in iSGS and whether it could become the first medication to slow down this scarring airway disease.",[84,85],"Idiopathic Subglottic Stenosis","Subglottic Stenosis (SGS)",[87,88,89,90],"Subglottic Stenosis","Idiopathic Subglottic stenosis","Airway Fibrosis","Pirfenidone","2026-06-12",{"date":93,"type":32},"2026-06-17",{"date":95,"type":21},"2026-12-01",{"date":97,"type":21},"2029-12-01",{"name":38,"class":39},1,{"id":101,"slug":102,"hasResults":12,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":12,"sex":17,"minAge":107,"maxAge":108,"enrollmentInfo":109,"targetDuration":4,"studyType":111,"phases":4,"briefSummary":112,"conditions":113,"keywords":115,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":99},"100628339","extended-interval-dosing-of-gentamicin-in-neonates-100628339","NCT07460349","Extended Interval Dosing of Gentamicin in Neonates","Extended Interval Dosing of Gentamicin in Neonates to Achieve Target Drug Concentrations","Inclusion Criteria:\n\n* Neonates up to 7 days of age,\n* Neonate must be on gentamicin, and\n* Gentamicin trough and peak levels must be available for the third dose of gentamicin.\n\nExclusion Criteria:\n\n* Incorrect dose for weight (+\u002F- 10% allowed to account for dose rounding)\n* Multiple levels from the same patient; only the first set of levels will be collected\n* Baseline renal dysfunction (e.g. congenital kidney disease)\n* On other nephrotoxic or ototoxic drugs concurrently with the first 3 days of gentamicin","0 Days","7 Days",{"count":110,"type":21},42,"OBSERVATIONAL","A previous pharmacy residency project was done 20 years ago looking at the best dosing for the antibiotic gentamicin for babies up to 7 days old. This study showed that giving the dose less often leads to better drug concentrations than giving the dose more often. Our gentamicin dosing at the Children's Hospital at London Health Sciences Centre is based on the better dosing from the study. This dosing is gentamicin 3 mg\u002Fkg every 24 hours for babies less than 35 weeks gestational age and 3.5 mg\u002Fkg every 24 hours for babies at least 35 weeks gestational age. These results were never published. Different dosing is used at different hospitals. It is important that we check that our gentamicin dosing is still reaching safe and effective drug concentrations in the current study. The study will look at the gentamicin drug concentrations of babies up to 7 days old, including premature and term babies. We will also confirm if the babies have kidney or hearing damage from gentamicin. We will compare the gentamicin drug concentrations from this study to the past data to see if the dosing is still the best. The results can help form a guideline for the Children's Hospital and surrounding hospitals.",[114],"Early Onset Sepsis",[116,117,118],"gentamicin","extended interval dosing","neonates","2026-06-05",{"date":121,"type":32},"2026-06-09",{"date":123,"type":21},"2026-06",{"date":125,"type":21},"2027-04",{"name":38,"class":39},{"id":128,"slug":129,"hasResults":12,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":12,"sex":17,"minAge":134,"maxAge":135,"enrollmentInfo":136,"targetDuration":4,"studyType":22,"phases":137,"briefSummary":138,"conditions":139,"keywords":141,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":149,"completionDateStruct":150,"leadSponsor":152,"locationsCount":99},"100640179","feasibility-of-structured-resistance-training-after-lower-extremity-fracture-100640179","NCT07629180","Feasibility of Structured Resistance Training After Lower Extremity Fracture","Feasibility and Impact of a Structured, Supervised Exercise Program Following Lower Extremity Fracture: A Pilot Controlled Study","Inclusion Criteria:\n\n* Adults aged 20 to 65 years\n* Diaphyseal femur or tibia fracture treated surgically with locked intramedullary nail fixation\n* Cleared for full weight bearing with adequate fracture healing and no major complications\n* Able to provide written informed consent in English without an interpreter\n* Able to understand instructions and safely participate in supervised exercise\n\nExclusion Criteria:\n\n* Bilateral fractures or open fractures; Polytrauma\n* Cognitive impairment affecting participation or ability to provide informed consent\n* Severe cardiac, respiratory, or neurological conditions that preclude exercise participation\n* Chronic pain syndromes or recent opioid dependence\n* Pre-existing severe lower limb disability\n* Requires an interpreter for consent or cannot follow exercise instructions independently\n* Unable to provide consent due to language barrier","20 Years","65 Years",{"count":79,"type":21},[24],"Adults recovering from surgically managed diaphyseal femur or tibia fractures often experience persistent weakness, pain, and functional limitations despite successful fracture healing. This prospective, non-randomized pilot study evaluates the feasibility and acceptability of a structured, supervised resistance training program initiated approximately 12 weeks after surgery, compared with usual postoperative care alone. The study will assess recruitment, adherence, retention, and protocol fidelity, and will collect exploratory patient-reported and physical function outcomes to inform the design of a future randomized controlled trial.",[140],"Lower Extremity Fractures",[142,143,144,145,146],"Femur Shaft fracture","Tibia Shaft Fracture","Postoperative Rehabilitation","Resistance Training","Lower extremity fracture","2026-06-01",{"date":119,"type":32},{"date":63,"type":21},{"date":151,"type":21},"2031-06-15",{"name":38,"class":39},{"id":154,"slug":155,"hasResults":12,"nctId":156,"briefTitle":157,"officialTitle":157,"acronym":4,"eligibilityCriteria":158,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":159,"targetDuration":4,"studyType":111,"phases":4,"briefSummary":161,"conditions":162,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":4},"100640081","assessing-the-impact-of-the-personalized-medicine-clinic-on-mental-health-outcomes-100640081","NCT07601477","Assessing the Impact of the Personalized Medicine Clinic on Mental Health Outcomes","Inclusion Criteria:\n\n* Depressive symptoms\n\nExclusion Criteria:\n\n* Patients who do not speak English\n* Patients with severe mental illness including hospitalized patients or patients with suicidal ideation",{"count":160,"type":21},200,"The aim of this study is to investigate if personalized dosing of antidepressant medications using information gathered at the Personalized Medicine Clinic can improve patients' mental health. The main question it aims to answer is if the Personalized Medicine Clinic can improve depressive symptoms based on the CES-D survey score.",[163,164,165,166],"Mental Health","Depressive Disorder","Pharmacogenetic Testing","Antidepressant","2026-05-21",{"date":169,"type":32},"2026-05-26",{"date":171,"type":21},"2026-07",{"date":173,"type":21},"2028-06",{"name":38,"class":39},{"id":176,"slug":177,"hasResults":12,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":181,"eligibilityCriteria":182,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":183,"targetDuration":4,"studyType":111,"phases":4,"briefSummary":185,"conditions":186,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":99},"100474012","testing-virtues-patient-care-sets-in-cardiac-patients-virtues-cardiac-care-100474012","NCT05452356","Testing VIRTUES Patient Care Sets in Cardiac Patients (VIRTUES Cardiac Care)","Testing of Patient Care Sets and Management of Cardiovascular Conditions Using a Virtual Platform","VIRTUES-CC","Inclusion Criteria:\n\n* Any patient with a cardiovascular condition.\n* Ability to provide informed consent.\n* Proficient in the English language.\n* Access to a device capable of running mobile application.\n* Used mobile technology within the past 3 months.\n\nExclusion Criteria:\n\n* Any medical condition making 1-month survival unlikely.",{"count":184,"type":21},2000,"Patients with various cardiac conditions (such as those who experience a heart attack) are increasing in Canada and are in need of appropriate cardiac rehabilitation and care. Many patients do not have access to local in-person cardiac clinics, particularly in rural regions of Canada. A user-friendly digital application with accessible educational resources and recommendations based on the most up to date clinical practice guidelines can help mitigate these issues. VIRTUES is a digital healthcare application that targets 11 modifiable modules as follows:\n\n1. antithrombotic management\n2. lipid management\n3. rate and rhythm control for atrial fibrillation\n4. heart failure care\n5. post myocardial infarction care\n6. blood sugar management\n7. blood pressure management\n8. physical activity\n9. healthy eating\n10. smoking cessation\n11. alcohol reduction\n\nOf the 11 total modules, the first 7 listed provide recommendations in VIRTUES. The remaining 4 (physical activity, healthy eating, smoking cessation and alcohol reduction) consist of simple referrals to existing recommendations (i.e., for healthy eating and physical exercise) and referrals to existing local programs (i.e., for smoking cessation and alcohol reduction). Thus, in this cohort study, the investigators will test the primary 7 modules with 200 patients per module for approximately one month each in order to obtain feedback on the usability of each module. The investigators will also conduct virtual focus group discussions to obtain open ended feedback on the application. This study will provide valuable feedback, which will be used to improve and adapt the VIRTUES platform.",[187,188,189,190,191],"Heart Diseases","Arrhythmias, Cardiac","Atrial Fibrillation","Cardiovascular Diseases","Pathologic Processes","2026-05-19",{"date":194,"type":32},"2026-05-22",{"date":196,"type":32},"2024-04-18",{"date":198,"type":21},"2028-09-30",{"name":38,"class":39},{"id":201,"slug":202,"hasResults":12,"nctId":203,"briefTitle":204,"officialTitle":205,"acronym":4,"eligibilityCriteria":206,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":207,"targetDuration":4,"studyType":22,"phases":209,"briefSummary":210,"conditions":211,"keywords":214,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":220,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":226,"locationsCount":99},"100640856","transcutaneous-auricular-vagus-nerve-stimulation-as-a-treatment-for-musculoskeletal-pain-in-cerebral-palsy-100640856","NCT07585292","Transcutaneous Auricular Vagus Nerve Stimulation as a Treatment for Musculoskeletal Pain in Cerebral Palsy","Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) for the Treatment of Chronic Musculoskeletal (MSK) Pain in Adults With Cerebral Palsy","Inclusion Criteria:\n\n* Diagnosis of cerebral palsy\n* Age ≥18 years\n* Chronic musculoskeletal pain present for ≥1 year\n* Moderate or greater pain severity (≥4\u002F10 on Numeric Pain Rating Scale)\n* Stable pain and\u002For anti-inflammatory medication dosing for ≥6 weeks\n\nExclusion Criteria:\n\n* Cardiovascular disease\n* Pacemaker or implanted electrical device\n* Cerebral shunt\n* Pregnancy or intent to become pregnant\n* Current infection or open wounds at electrode sites",{"count":208,"type":21},32,[24],"This randomized, double-blind, sham-controlled clinical trial will evaluate the safety and efficacy of a 30-day home-based transcutaneous auricular vagus nerve stimulation (taVNS) intervention in adults with cerebral palsy (CP) and chronic musculoskeletal pain. Participants will be randomized to receive either active taVNS targeting the auricular branch of the vagus nerve or sham stimulation delivered to the earlobe. The primary outcomes are changes in musculoskeletal pain severity and pain interference, as well as safety assessed through treatment-emergent adverse events. Exploratory outcomes include health-related quality of life, depression, fatigue, spasticity, systemic inflammatory biomarkers, and blinding success.",[212,213],"Cerebral Palsy (CP)","Musculoskeletal Pain",[215,216,217,218],"vagus nerve stimulation","musculoskeletal pain","taVNS","cerebral palsy","2026-05-07",{"date":221,"type":32},"2026-05-13",{"date":223,"type":21},"2026-10-01",{"date":225,"type":21},"2029-05-31",{"name":38,"class":39},{"id":228,"slug":229,"hasResults":12,"nctId":230,"briefTitle":231,"officialTitle":232,"acronym":4,"eligibilityCriteria":233,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":234,"targetDuration":4,"studyType":22,"phases":235,"briefSummary":236,"conditions":237,"keywords":240,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":244,"startDateStruct":246,"completionDateStruct":247,"leadSponsor":249,"locationsCount":99},"100637499","transcutaneous-auricular-vagus-nerve-stimulation-as-a-treatment-for-neuropathic-pain-following-spinal-cord-injury-100637499","NCT07588711","Transcutaneous Auricular Vagus Nerve Stimulation as a Treatment for Neuropathic Pain Following Spinal Cord Injury","Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) as an Anti-inflammatory Strategy for the Treatment of Neuropathic Pain Following Spinal Cord Injury","Inclusion Criteria:\n\n* SCI of any level or severity\n* 18 years of age or older\n* current neuropathic pain\n* on no medications or on a stable prescribed dose (no change in prior 6-weeks) of anti-inflammatory, pain medications and\u002For depression medications\n\nExclusion Criteria:\n\n* Prone to autonomic dysreflexia\n* presence of cardiovascular disease\n* pacemaker or other implanted electrical device\n* cerebral shunts\n* epilepsy\n* pregnant or attempting to become pregnant\n* current wound\u002Finfection\n* unstable dose of prescribed anti-inflammatory, depression, or pain medications within past 6-weeks.",{"count":208,"type":21},[24],"This pilot randomized, double-blind, sham-controlled clinical investigation will evaluate the feasibility and safety of a 30-day home-based transcutaneous auricular vagus nerve stimulation (taVNS) intervention in adults with spinal cord injury (SCI) and neuropathic pain. Participants will be randomized to receive either active taVNS targeting the auricular branch of the vagus nerve or sham taVNS delivered to the earlobe. Primary outcomes include feasibility, safety, adherence, acceptability, and blinding success. Exploratory outcomes include changes in neuropathic pain, systemic inflammatory biomarkers, vagal tone assessed via heart rate variability, and quality of life.",[238,239],"Spinal Cord Injury","Neuropathic Pain",[215,241,242,243,217],"inflammation","spinal cord injury","neuropathic pain",{"date":245,"type":32},"2026-05-15",{"date":223,"type":21},{"date":248,"type":21},"2028-08-30",{"name":38,"class":39},{"id":251,"slug":252,"hasResults":12,"nctId":253,"briefTitle":254,"officialTitle":255,"acronym":4,"eligibilityCriteria":256,"healthyVolunteers":12,"sex":17,"minAge":257,"maxAge":4,"enrollmentInfo":258,"targetDuration":4,"studyType":22,"phases":260,"briefSummary":261,"conditions":262,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":265,"lastUpdatePostDateStruct":266,"startDateStruct":268,"completionDateStruct":269,"leadSponsor":271,"locationsCount":4},"100640798","early-screening-for-cardiac-amyloid-using-a-history-of-bilateral-carpal-tunnel-syndrome-100640798","NCT07580872","Early Screening for Cardiac Amyloid Using a History of Bilateral Carpal Tunnel Syndrome","Investigations in Early Screening for Cardiac Amyloid Through History of Bilateral Carpal Tunnel Syndrome","Inclusion Criteria:\n\n* Patients aged 55 and older at the time of surgery.\n* Patients who have had bilateral carpal tunnel release surgery (i.e., at least two carpal tunnel release surgeries, one for each hand).\n* Patients who underwent surgery between the years 2010-2015.\n\nExclusion Criteria:\n\n* Patients under the age of 55 at time of surgery.\n* Patients who had unilateral carpal tunnel release surgery or surgery on only one hand.\n* Patients known alternative neurologic diagnosis explaining CTS\n* Patients with incomplete medical records\n* Patient denies PYP scan\n* Previously diagnosed amyloidosis through previous positive PYP, medical notes or self-reported\n* Patients with prior negative amyloid work up\n* Cognitive\u002Fcommunication issues without available translation support","55 Years",{"count":259,"type":21},139,[24],"Cardiac amyloidosis is a condition where abnormal protein deposits build up in the heart, making it stiff and causing it to work less effectively. One common type is caused by a normal blood protein called transthyretin (TTR), which can become unstable and form these deposits. When this happens, it is called ATTR-CM, a form of heart disease caused by TTR protein buildup. This can lead to symptoms like tiredness, shortness of breath, or swelling.\n\nBilateral carpal tunnel syndrome (CTS) is recognized as an early clinical sign of systemic amyloidosis, especially in the context of TTR amyloidosis, where amyloid deposits accumulate in the median nerve. Early identification of cardiac amyloidosis, particularly in patients with bilateral CTS, may allow for earlier intervention with disease-modifying therapies, such as tafamidis, which has been shown to improve survival and reduce hospitalizations in patients with cardiac amyloidosis.\n\nThe purpose of this study is to identify patients to evaluate them for previously undiagnosed cardiac amyloidosis. The collected information will help estimate the prevalence of cardiac amyloidosis among participants with prior bilateral CTS using a PYP nuclear scan (technetium-99m pyrophosphate scan). A PYP scan is a special heart imaging test that helps doctors see if certain abnormal proteins are building up in the heart. It's mainly used to help diagnose cardiac amyloidosis.",[263,264],"Bilateral Carpal Tunnel Syndrome (Diagnosis)","Cardiac Amyloidosis","2026-05-05",{"date":267,"type":32},"2026-05-12",{"date":171,"type":21},{"date":270,"type":21},"2028-01",{"name":38,"class":39},{"id":273,"slug":274,"hasResults":12,"nctId":275,"briefTitle":276,"officialTitle":277,"acronym":278,"eligibilityCriteria":279,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":280,"targetDuration":4,"studyType":22,"phases":282,"briefSummary":283,"conditions":284,"keywords":287,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":288,"lastUpdatePostDateStruct":289,"startDateStruct":291,"completionDateStruct":293,"leadSponsor":295,"locationsCount":99},"100580084","assessment-of-a-wearable-ultrafiltration-device-100580084","NCT06832696","Assessment of a Wearable Ultrafiltration Device","Initial Assessment of a Wearable Residual Ultrafiltration Device (RUF-D) to Address Challenges Associated With Inadequate Volume Management in Hemodialysis Patients","RUF-D","Inclusion Criteria:\n\n* At least one of the following:\n\n  1. Average per-session IDWG ≥ 4.0% of dry weight in the last month\n  2. Inability to consistently achieve dry weight with current HD\n  3. Need for additional HD treatments to achieve prescribed dry weight\n* HD sessions three times\u002Fweek\n* Age ≥ 18 years\n* Dialyzing via central venous access\n* Willing and able to provide informed consent\n\nExclusion Criteria:\n\n* Active infections\n* Non-compliance to hemodialysis prescription\u002Fschedule",{"count":281,"type":21},18,[24],"Kidney failure is common. In some people the ability of the kidneys to clean poisons out of the blood gets so low they need to be hooked up to a machine three times a week to do it for them. This is called dialysis. Unfortunately, although this treatment removes those waste products, people who need dialysis die much more often than people who don't need dialysis. Dialysis causes extreme stress on the body and leads to many organs being damaged.\n\nRemoving fluid from the body quickly causes the equivalent of repeated little heart attacks or little strokes in the brain. Many patients struggle to tolerate having all the fluid that they have drunk since their last dialysis session removed- without unpleasant symptoms of dangerously low blood pressure (which makes the damage worse).\n\nDialysis treatments can be done more slowly or more often, but that means having to spend a lot more time at the hospital and is difficult for the health system to be able to provide the extra treatment time.\n\nCould extra fluid be removed in between dialysis sessions? Up to now there has not been a way to effectively do this. Investigators have now designed and built an entirely new, very small and very simplified, device that can do part of what a dialysis machine does. It doesn't clean the blood or replace the need for conventional dialysis sessions, but it can provide additional and gentle removal of fluid which wasn't able to be taken off during a standard treatment session.\n\nIf this study is successful, it will be the first time that a wearable device has been successfully built and used to take off extra fluid when dialysis patients are not in the hospital. The ability to do this opens up the possibility of, 1) helping to treat patients (both making people feel better and live longer) who can't tolerate getting off all the fluid in the short 3-4 hours they are on the dialysis machine in the hospital, and 2) helping patients who feel OK having the fluid taken off but are silently being subjected to damage to their organs due to the rapid removal, have reduced damage.",[285,286],"Hemodialysis","Ultrafiltration",[285,286],"2026-04-28",{"date":290,"type":32},"2026-04-29",{"date":292,"type":21},"2026-07-01",{"date":294,"type":21},"2027-12-31",{"name":38,"class":39},{"id":297,"slug":298,"hasResults":12,"nctId":299,"briefTitle":300,"officialTitle":301,"acronym":4,"eligibilityCriteria":302,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":303,"targetDuration":4,"studyType":22,"phases":304,"briefSummary":305,"conditions":306,"keywords":308,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":288,"lastUpdatePostDateStruct":311,"startDateStruct":313,"completionDateStruct":315,"leadSponsor":317,"locationsCount":318},"100518566","an-extension-to-assess-the-effect-of-expanded-dialysis-on-patient-reported-symptoms-using-levil-100518566","NCT06032208","An Extension to Assess the Effect of Expanded Dialysis on Patient Reported Symptoms Using LEVIL","An Extension of an Interventional Study to Assess the Effect of Expanded Dialysis (HDx-Theranova) on Patient Reported Symptoms Using London Evaluation of Illness (LEVIL)","Inclusion Criteria:\n\n* Conventional thrice weekly HD schedule\n* Must be on chronic hemodialysis for at least 3 months\n* Age ≥18 years\n* Willing and able to give informed consent\n\nExclusion Criteria:\n\n* Active infection (may enroll once infection is cleared)\n* Patients receiving daily hemodialysis treatment\n* Patients currently receiving Hemodiafiltration (HDF), Hemofiltration (HF) or Isolated ultrafiltration (ISO UF) more than once in three months\n* Visual impairment\n* History of neurocognitive impairment\n* History of stroke (CVA)",{"count":49,"type":21},[24],"Investigators know that many patients who are on dialysis suffer from burden of unwanted symptoms, which can affect quality of life. The understanding and treatment of symptom burden by healthcare providers is limited and should be recognized as a high priority in the care of the dialysis population. In this study, the investigators will be assessing symptom burden using the London Evaluation of Illness \"LEVIL,\" an application based platform where patients self-report their symptoms with one to three hemodialysis treatments per week for 28 weeks. The investigators would like to compare the currently available dialyzer with a new dialyzer that is capable of removing solutes of higher molecular weight that may or may not cause patients to experience symptoms related to increased amounts of toxins in their blood.",[307],"End Stage Renal Disease",[285,309,310],"Large middle molecules","Theranova",{"date":312,"type":32},"2026-05-04",{"date":314,"type":32},"2024-03-01",{"date":316,"type":21},"2026-12-31",{"name":38,"class":39},4,{"id":320,"slug":321,"hasResults":12,"nctId":322,"briefTitle":323,"officialTitle":324,"acronym":4,"eligibilityCriteria":325,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":326,"targetDuration":4,"studyType":111,"phases":4,"briefSummary":328,"conditions":329,"keywords":332,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":288,"lastUpdatePostDateStruct":334,"startDateStruct":335,"completionDateStruct":337,"leadSponsor":338,"locationsCount":339},"100417895","fluid-intake-after-hemodialysis-100417895","NCT04721652","Fluid Intake After Hemodialysis","Fluid Intake After Hemodialysis: Investigating the Relationship Between Time and Weight Gain During the Interdialytic Interval","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Thrice weekly maintenance hemodialysis\n* Willing and able to provide written informed consent\n\nExclusion Criteria:\n\n* Diabetes Mellitus\n* Residual Urinary Volume \\> 500 ml\u002Fday\n* Being able to self-monitor one's body weight and blood pressure",{"count":327,"type":21},20,"Interdialytic weight gain determines how much fluid (ultrafiltration) has to be removed during each hemodialysis session. High ultrafiltration volumes stress the organism and lead to a higher risk of death. Thirst is the main driving factor of interdialytic weight gain, and thirst is mainly driven by salt intake, molecules that increase blood tonicity (such as sugar in diabetics) and fluid loss (such as in dehydration and blood loss). It has been speculated that fluid loss during hemodialysis could increase the sense of thirst immediately following dialysis, but this statement requires further evidence.",[330,331],"Chronic Kidney Disease Requiring Chronic Dialysis","Interdialytic Weight Gain",[285,331,333],"Thirst",{"date":312,"type":32},{"date":336,"type":32},"2021-02-25",{"date":316,"type":21},{"name":38,"class":39},2,{"id":341,"slug":342,"hasResults":12,"nctId":343,"briefTitle":344,"officialTitle":345,"acronym":346,"eligibilityCriteria":347,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":135,"enrollmentInfo":348,"targetDuration":4,"studyType":22,"phases":350,"briefSummary":351,"conditions":352,"keywords":355,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":359,"lastUpdatePostDateStruct":360,"startDateStruct":362,"completionDateStruct":364,"leadSponsor":366,"locationsCount":99},"100518843","sensory-motor-arousal-regulation-treatment-smart-study-100518843","NCT06035809","Sensory Motor Arousal Regulation Treatment (SMART) Study","The Effects of Sensory Motor Arousal Regulation Treatment (SMART) on Adults With PTSD","SMART","Inclusion Criteria:\n\n1. Adults, aged 18-65\n2. A primary diagnosis of PTSD as determined by our pre-treatment assessment\n3. Ability to provide informed consent\n4. Fluency in written and spoken English (to be able to complete assessments)\n5. Lives within 30km of London, ON\n\nExclusion Criteria:\n\n1. any implants, conditions, etc. that do not comply with 7T (Tesla) fMRI research safety standards (e.g., pacemaker, pregnancy\u002Fpossible pregnancy)\n2. history of significant head injury\u002Flengthy loss of consciousness (e.g., a Glasgow Coma Scale Score \\\u003C 15 at the time of incident as assessed retrospectively by participant)\n3. significant untreated medical illness\n4. history of neurological or neurodevelopmental disorder\n5. history of any pervasive developmental disorder\n6. lifetime bipolar or psychotic disorder\n7. alcohol\u002Fsubstance abuse or dependence within the last 3 months\n8. extensive narcotic use (e.g., fentanyl, oxycodone, etc.)\n9. anyone who would not be suitable for short-term treatment (as determined by our pre-treatment assessment)\n10. suicide attempt in last 6 months",{"count":349,"type":21},80,[24],"This study will investigate whether a movement and body-based treatment can benefit adults with Post-traumatic Stress Disorder (PTSD). The treatment is called Sensory Motor Arousal Regulation Treatment, or \"SMART\", and study participation involves 8 sessions of SMART, as well as pre-treatment, post-treatment, and 3-month follow-up assessments.",[353,354],"PTSD","Post-traumatic Stress Disorder",[353,354,356,357,358],"Body-based trauma therapy","Movement-based trauma therapy","Sensory-motor","2026-04-17",{"date":361,"type":32},"2026-04-22",{"date":363,"type":32},"2026-04-15",{"date":365,"type":21},"2028-04-15",{"name":38,"class":39},{"id":368,"slug":369,"hasResults":12,"nctId":370,"briefTitle":371,"officialTitle":372,"acronym":4,"eligibilityCriteria":373,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":374,"targetDuration":4,"studyType":22,"phases":375,"briefSummary":377,"conditions":378,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":363,"lastUpdatePostDateStruct":381,"startDateStruct":383,"completionDateStruct":385,"leadSponsor":386,"locationsCount":99},"100608450","early-phase-1-oral-carnitine-in-heart-failure-patients-100608450","NCT07201714","Oral Carnitine in Heart Failure Patients","Oral L-Carnitine Supplementation in Cardiorenal Heart Failure Patients","Inclusion Criteria:\n\n* Clinical-pathological diagnosis of heart failure with some degree of cardiorenal syndrome\n* Stage 1, 2, 3a, 3b, or 4 chronic kidney disease\n* Age ≥ 18 years\n* Able to speak and read English\n* Willing and able to provide consent\n\nExclusion Criteria:\n\n* Estimated GFR \\\u003C15 mL\u002Fmin\u002F1.73m2 or Stage 5 chronic kidney disease\n* Currently undergoing renal replacement therapy of any kind\n* Pregnant, breastfeeding or intending pregnancy\n* History of seizures of any type\n* Known allergy to levocarnitine, magnesium stearate, microcrystalline cellulose or povidone\n* Unable to provide consent",{"count":327,"type":21},[376],"EARLY_PHASE1","Heart failure is a condition in which the heart is unable to pump blood effectively, leading to symptoms like being more tired, shortness of breath, and swelling in the body. Carnitine is a naturally occurring substance in the body that plays a role in turning fat into energy. This study will determine whether oral L-Carnitine supplementation can improve symptoms, enhance heart function and possibly improve the quality of life in individuals with heart failure.",[379,380],"Heart Failure","Carnitine Deficiency",{"date":382,"type":32},"2026-04-20",{"date":384,"type":32},"2025-11-12",{"date":316,"type":21},{"name":38,"class":39},{"id":388,"slug":389,"hasResults":12,"nctId":390,"briefTitle":391,"officialTitle":392,"acronym":393,"eligibilityCriteria":394,"healthyVolunteers":12,"sex":395,"minAge":4,"maxAge":4,"enrollmentInfo":396,"targetDuration":4,"studyType":22,"phases":397,"briefSummary":398,"conditions":399,"keywords":401,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":404,"lastUpdatePostDateStruct":405,"startDateStruct":407,"completionDateStruct":408,"leadSponsor":410,"locationsCount":99},"100632224","evaluation-of-a-prostate-targeted-pet-imaging-system-p-pet-for-detecting-prostate-cancer-100632224","NCT07510906","Evaluation of a Prostate-Targeted PET Imaging System (P-PET) for Detecting Prostate Cancer","A Pilot Study to Evaluate the Imaging Capability of a Novel Prostate-targeted PET System (P-PET) to Detect Prostate Cancer","P-PET","Inclusion Criteria:\n\n* Qualitative comparison of PET scans acquired by the P-PET vs. WB PET\n\nExclusion Criteria:\n\n* Unable to comply with the length of scan time due to the study imaging.","MALE",{"count":7,"type":21},[24],"The goal of this study is to evaluate the imaging capabilities of a new prostate-targeted PET system (P-PET) and determine whether it could be useful in detecting prostate cancer by comparing SOC whole body PET imaging. This pilot study will include adult men who have been diagnosed with or are suspected to have prostate cancer. Participants will undergo a standard-of-care PET\u002FCT scan followed by an additional P-PET scan designed to provide detailed images of the prostate. The images from the two scans to assess how well the P-PET system can detect prostate cancer.",[400],"Prostate Cancer",[400,402,403],"PSMA PET Scan","Dynamic PET Scan","2026-03-31",{"date":406,"type":32},"2026-04-06",{"date":292,"type":21},{"date":409,"type":21},"2028-04-01",{"name":38,"class":39},{"id":412,"slug":413,"hasResults":12,"nctId":414,"briefTitle":415,"officialTitle":415,"acronym":416,"eligibilityCriteria":417,"healthyVolunteers":12,"sex":17,"minAge":418,"maxAge":419,"enrollmentInfo":420,"targetDuration":4,"studyType":111,"phases":4,"briefSummary":421,"conditions":422,"keywords":424,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":428,"lastUpdatePostDateStruct":429,"startDateStruct":431,"completionDateStruct":433,"leadSponsor":435,"locationsCount":4},"100625392","biomind-biomarkers-for-the-molecular-identification-of-neurodegenerative-dementia---improving-access-to-alzheimers-disease-diagnostics-a-pragmatic-system-level-intervention-100625392","NCT07422038","BioMIND (Biomarkers for the Molecular Identification of Neurodegenerative Dementia) - Improving Access to Alzheimer's Disease Diagnostics: A Pragmatic System Level Intervention","BioMIND 2","Inclusion Criteria:\n\n1. Individual with MCI or early dementia (if not yet diagnosed, individuals with amnestic changes in memory as shown on MoCA)\n2. MoCA score must be 10 to 28 inclusive\n3. Age 50 to 90 years inclusive\n\nExclusion Criteria:\n\n1. Participants who fulfill diagnostic criteria for MCI or dementia\u002Fmild or major neurocognitive disorder suspected to be due to any etiology other than AD (eg, MCI\u002Fdementia due to frontotemporal lobar degeneration, diffuse Lewy body disease, Parkinson's disease, cerebrovascular disease, normal pressure hydrocephalus, head injury, drug or alcohol abuse\u002Fdependence, anoxic brain injury, etc).\n2. Presence of any neurological, psychiatric, or medical conditions associated with a long-term risk of significant cognitive impairment or dementia including, but not limited to, pre-manifest Huntington's disease, multiple sclerosis, Parkinson's disease, Down's syndrome, active alcohol\u002Fdrug abuse or major psychiatric disorders including, but not limited to, schizophrenia, schizoaffective disorder, or bipolar affective disorder or current episode of major depressive disorder.\n3. Current or history within the past 2 years of psychiatric diagnosis or symptoms (eg, hallucinations, major depression, or delusions) that, in the opinion of the investigator, could interfere with study procedures\n4. Pregnant women and breastfeeding mothers.\n5. Individuals who are unable to complete assessments in the English language.\n6. Individuals who cannot provide consent","50 Years","90 Years",{"count":160,"type":21},"The BioMIND (Biomarkers for the Molecular Identification of Neurodegenerative Dementia) pilot study was launched at Parkwood Hospital in response to national calls for implementation of biomarker diagnostics in Canada. It evaluated the feasibility, impact, and equity of introducing blood biomarker testing, lumbar punctures, and amyloid Positron Emission Tomography (PET) scans into clinical pathways. The study found that the Biomarker-First pathway significantly reduced the time from referral to diagnosis (195 versus 533 days - a difference of 318 days), demonstrating the value in implementing clinical biomarkers to bypass bottlenecks created by the need for specialist assessments. Building on these findings, the next phase of BioMIND is aimed at reducing wait times for biomarker diagnostics for patients with symptoms suggestive of mild cognitive impairment (MCI) and early AD.\n\nThe aim is to understand these wait times to biomarker testing using a nurse-led triage support tool. Group A participants will be pre-screened using this tool that includes the eligibility criteria for the study. This will help understand, out of everybody coming to the Aging Brain and Memory Clinic (ABMC) who've indicated interest in research, which people would be eligible to receive AD biomarkers if they were clinically available. Comparison of Group A's time to diagnosis with Group B and C's, who would have had a specialist appointment within 18 months and were referred to research to receive AD biomarkers through this study.",[423],"Alzheimer Disease (AD)",[425,426,427],"mild cognitive impairment","dementia","biomarkers","2026-02-18",{"date":430,"type":32},"2026-02-19",{"date":432,"type":21},"2026-02-01",{"date":434,"type":21},"2027-09-01",{"name":38,"class":39},{"id":437,"slug":438,"hasResults":12,"nctId":439,"briefTitle":440,"officialTitle":441,"acronym":4,"eligibilityCriteria":442,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":443,"targetDuration":4,"studyType":22,"phases":445,"briefSummary":447,"conditions":448,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":428,"lastUpdatePostDateStruct":450,"startDateStruct":452,"completionDateStruct":454,"leadSponsor":456,"locationsCount":339},"100391270","phase-3-heparin-vs-placebo-for-cardiac-catheterization-100391270","NCT04374799","Heparin vs Placebo for Cardiac Catheterization","A Randomized Trial of Heparin vs Placebo in Patients Undergoing Cardiac Catheterization Via the Trans-radial Approach","Inclusion Criteria:\n\n* diagnostic cardiac catheterization; Small size sheath; patency of the ulno-palmar circulation\n\nExclusion Criteria:\n\nabnormal ulno-palmar circulation; Prior radial artery thrombosis; Prior surgery close to the access site; Emergent cardiac catheterization; History of HIT or allergy to heparin; Patients requiring anticoagulation",{"count":444,"type":21},1623,[446],"PHASE3","Patients undergoing cardiac catheterization will be randomized to 3 groups: no anticoagulant, low dose anticoagulant and high dose anticoagulant.",[449],"Cardiac Disease",{"date":451,"type":32},"2026-02-20",{"date":453,"type":32},"2020-10-05",{"date":455,"type":21},"2026-12",{"name":38,"class":39},{"id":458,"slug":459,"hasResults":12,"nctId":460,"briefTitle":461,"officialTitle":462,"acronym":4,"eligibilityCriteria":463,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":464,"targetDuration":4,"studyType":111,"phases":4,"briefSummary":466,"conditions":467,"keywords":469,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":474,"lastUpdatePostDateStruct":475,"startDateStruct":476,"completionDateStruct":478,"leadSponsor":480,"locationsCount":4},"100625363","effect-of-epilepsy-and-antiepileptic-drug-therapy-on-gastric-motility-and-emptying-with-point-of-care-gastric-ultrasound-100625363","NCT07421661","Effect of Epilepsy and Antiepileptic Drug Therapy on Gastric Motility and Emptying With Point-Of-Care Gastric Ultrasound","Effect of Epilepsy and Antiepileptic Drug Therapy on Gastric Motility and Emptying by Comparing Gastric Volume With Point-Of-Care Gastric Ultrasound in Epileptic Patients After Standard CAS\u002FASA Fasting Guidelines","Inclusion Criteria:\n\n1. Diagnosis of epilepsy (confirmed by history or medical records and classified as per 2025 ILAE classification for seizures).\n2. Scheduled for elective neurologic (e.g., epilepsy surgery) or non-neurologic surgery under anesthesia.\n3. 18 years of age or older.\n4. Adherence to standard fasting guidelines (verified by patient report).\n\nExclusion Criteria:\n\n1. Refusal\u002Fwithdrawal of consent.\n2. Noncompliance with fasting guidelines.\n3. Pregnancy.\n4. Patients with continuous treatment on GLP\u002FGIP 1 analogues without a washout period.\n5. Parkinsons patients with proven gastroparesis.\n6. Diabetic neuropathy with gastroparesis\n7. Patients on Prokinetic agents (Metoclopramide\u002F Erythromycin)\n8. Neuro muscular\u002F neurodegenerative disorders with gastroparesis.\n9. Uncontrolled hypothyroidism.\n10. Bowel obstruction",{"count":465,"type":21},30,"People with epilepsy often need surgery, but it is not fully known whether their stomachs empty food and liquids at the same rate as people without epilepsy. Some seizure medications, special diets, and nerve changes related to epilepsy may slow digestion, which could increase the risk of stomach contents entering the lungs during anesthesia. The purpose of this study is to find out whether people with epilepsy still have food or liquid in their stomachs before surgery, even after following standard fasting rules. To do this, researchers will use a simple bedside ultrasound scan of the stomach before surgery. The scan takes only a few minutes and does not involve needles, radiation, or pain and will determine what food and\u002For liquid may be present in the stomach before surgery. About 30 adults with epilepsy scheduled for surgery will take part in this study. The results of this study may help to inform whether or not the surgical fasting guidelines for epilepsy patients need to be modified. This is a prospective, observational study that will take place at University Hospital, London Health Sciences Centre.",[468],"Epilepsy",[470,471,472,468,473],"POCUS","Gastric Volume","Anesthesia","Fasting Guidelines","2026-02-12",{"date":430,"type":32},{"date":477,"type":21},"2026-04-01",{"date":479,"type":21},"2028-04-30",{"name":38,"class":39},{"id":482,"slug":483,"hasResults":12,"nctId":484,"briefTitle":485,"officialTitle":486,"acronym":487,"eligibilityCriteria":488,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":489,"targetDuration":4,"studyType":22,"phases":490,"briefSummary":492,"conditions":493,"keywords":499,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":503,"lastUpdatePostDateStruct":504,"startDateStruct":506,"completionDateStruct":508,"leadSponsor":510,"locationsCount":339},"100607414","phase-2-neoadjuvant-sbrt-with-intratumoural-pembrolizumab-followed-by-neoadjuvant-chemotherapy-in-breast-cancer-100607414","NCT07188246","Neoadjuvant, SBRT With Intratumoural Pembrolizumab Followed by Neoadjuvant Chemotherapy in Breast Cancer","A Trial of Neoadjuvant, Hypofractionated Radiation, With Intratumoural Pembrolizumab Followed by Neoadjuvant Chemotherapy, in Stage 3 or High-risk Stage 2 Breast Cancer","BRINK","Inclusion Criteria:\n\n1. Invasive ductal carcinoma of any subtype (including invasive mammary carcinoma with lobular features), excluding sarcomatous, signet or metaplastic subtypes.\n2. Invasive mammary carcinoma of stages IIB - III (excluding inflammatory breast cancer). Stage IIA is eligible for triple negative and HER2+ breast cancers.\n\n   a. Clinical staging based on AJCC 8th edition.\n3. Lesion palpable by treating physician.\n4. Plan to be treated with neoadjuvant chemotherapy.\n5. Able to tolerate core needle biopsies and pembrolizumab injection.\n6. 18 years of age or older.\n7. Able to provide informed consent.\n\nExclusion Criteria:\n\n1. Any serious medical comorbidities or other contraindications to radiotherapy, chemotherapy, or surgery (e.g., uncontrolled diabetes, serious heart condition, etc).\n2. Prior treatment for current breast cancer.\n3. Previous radiation therapy to the same breast.\n4. Inflammatory breast carcinoma.\n5. Invasive mammary carcinoma with sarcomatous, signet cell or metaplastic subtypes.\n6. Recurrent breast cancer.\n7. Clinical or radiologic evidence or suspicion of distant metastatic disease (metastatic workup that requires additional imaging to follow-up on suspicious findings will exclude patients).\n8. Any collagen vascular disease precluding radiotherapy at the discretion of the treating radiation oncologist (particularly lupus, scleroderma, dermatomyositis, psoriatic arthritis).\n9. No prior stem cell transplantation.\n10. Any poorly controlled autoimmune conditions.\n11. Current use of corticosteroids or immunosuppressants.\n12. Any other malignancy at any site (except non-melanomatous skin cancer) \\\u003C5 years prior to study enrollment. Synchronous bilateral breast cancers are acceptable.\n13. Inability to tolerate core needle biopsies or pembrolizumab injection.\n14. Pregnant or lactating.\n15. Under 18 years of age.\n16. Inability or unwillingness to provide informed consent.\n17. Inability or unwillingness to complete study assessments\u002Finterventions and follow-up assessments.",{"count":79,"type":21},[491],"PHASE2","This study will evaluate the immune-priming effects of stereotactic body radiation therapy (SBRT) regimen coupled with two injections of pembrolizumab in high-risk primary breast carcinoma prior to neoadjuvant chemotherapy. Preliminary results from the investigators' local TRIO Trial suggest that SBRT prior to neoadjuvant chemotherapy (NAC) may result in improved response rates due to the combined effect of radiation therapy (RT) and chemotherapy. The investigators aim to augment this effect with the addition of pembrolizumab, a monoclonal antibody that binds to and blocks programmed cell death protein 1 (PD-1).",[494,495,496,497,498],"Breast Cancer","Breast Cancer Stage II","Breast Cancer Stage III","Breast Cancer Invasive","Breast Cancer Triple Negative",[500,501,502],"Immunotherapy","Pembrolizumab","Breast SBRT","2026-02-09",{"date":505,"type":32},"2026-02-11",{"date":507,"type":32},"2026-01-19",{"date":509,"type":21},"2029-02",{"name":38,"class":39},{"id":512,"slug":513,"hasResults":12,"nctId":514,"briefTitle":515,"officialTitle":515,"acronym":4,"eligibilityCriteria":516,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":517,"enrollmentInfo":518,"targetDuration":4,"studyType":22,"phases":520,"briefSummary":521,"conditions":522,"keywords":525,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":530,"lastUpdatePostDateStruct":531,"startDateStruct":533,"completionDateStruct":534,"leadSponsor":536,"locationsCount":99},"100298518","health-education-vs-meditation-in-irreversible-age-related-vision-loss-patients-and-their-caregivers-100298518","NCT03166072","Health Education vs Meditation in Irreversible Age-Related Vision Loss Patients and Their Caregivers","Inclusion Criteria:\n\n* Patients with irreversible age-related vision loss (IARVL) and have ongoing significant disability and\u002For their caregivers who agree to consent.\n* IARVL patients between age 60 to 85 years or caregivers between 18 to 85 years.\n* Deemed competent to provide individual consent to participate.\n* Speak and understand English without requirement for interpretation or assistance.\n* Have no significant self-reported or physician diagnosed mental health disorder other than depressive and\u002For anxiety symptoms.\n* Have either a minimum of CES-D 20-item scale score of 16 OR a minimum of 8 on the Hospital Anxiety Scale (HADS-A) 7-item sub-scale.\n* Have sufficient hearing to be able to follow verbal instructions\n* Ability to sit independently without physical discomfort for 30 minutes.\n* Willing and able to attend, via Microsoft TEAMS software, the four initial training sessions of MEDITATION or HEP and at least 6 follow-up sessions.\n* Willing to dedicate 33 minutes per day to their assigned home practice.\n\nExclusion Criteria:\n\n* Inability to provide informed consent.\n* Dementia as defined by MoCA \\\u003C 21.\n* Have significant suicidal ideation as per self-report (CES-D = 3 on item question 14 and\u002For 15).\n* Have severe depression CES-D ≥ 24.\n* Participating in other similar studies.\n* Have a lifetime diagnosis of self-reported other mental disorders, including bipolar I or II disorder, primary psychotic disorder (schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder).\n* Self-reported substance abuse or dependence within the past 3 months.\n* Have an acutely unstable medical illnesses, including delirium or acute cerebrovascular or cardiovascular events within the last 6 months.\n* Have a terminal medical diagnosis with prognosis of less than 12 months.\n* Having any planned changes to mood-altering medications at the time of enrollment for the next 12 weeks.","85 Years",{"count":519,"type":21},150,[24],"Investigators aim to assess the feasibility of delivering two augmentation interventions, Meditation and a Health Enhancement Program, for potentially enhancing the quality of life and mental health of Irreversible Age-Related Vision Loss (IARVL) patients and\u002For their caregivers.",[523,524],"Low Vision, One Eye, Unspecified Eye","Low Vision Blindness",[526,58,527,528,529],"Irreversible age-related vision loss","Meditation","Pilot study","Quality of life","2026-01-30",{"date":532,"type":32},"2026-02-03",{"date":382,"type":21},{"date":535,"type":21},"2027-12-20",{"name":38,"class":39},{"id":538,"slug":539,"hasResults":12,"nctId":540,"briefTitle":541,"officialTitle":542,"acronym":543,"eligibilityCriteria":544,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":545,"targetDuration":4,"studyType":111,"phases":4,"briefSummary":547,"conditions":548,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":550,"lastUpdatePostDateStruct":551,"startDateStruct":552,"completionDateStruct":554,"leadSponsor":556,"locationsCount":557},"100462795","neurologic-physiology-after-removal-of-therapy-neupart-100462795","NCT05306327","Neurologic Physiology After Removal of Therapy (NeuPaRT)","Neurologic Physiology After Removal of Therapy (NeuPaRT): Pilot Multicentre Feasibility Study","NeuPaRT","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Plan for the withdrawal of life sustaining measures (WLSM)\n3. Attending physician anticipates patient will die within 24 hours of the withdrawal of life sustaining measures\n4. Patient has an indwelling arterial cannula for monitoring blood pressure\n\nExclusion Criteria:\n\n1. Brain death or plan for Neurologic Determination of Death (NDD)\n2. Injuries that anatomically preclude the use of neurologic monitoring",{"count":546,"type":21},158,"The purpose of this study is to determine when brain function stops compared to when the heart stops by monitoring electrical brain activity in patients who are taken off life support and progress to death in the intensive care unit.",[549],"Determination of Death","2026-01-28",{"date":530,"type":32},{"date":553,"type":32},"2022-10-18",{"date":555,"type":21},"2027-03",{"name":38,"class":39},5,{"id":559,"slug":560,"hasResults":12,"nctId":561,"briefTitle":562,"officialTitle":563,"acronym":564,"eligibilityCriteria":565,"healthyVolunteers":12,"sex":17,"minAge":566,"maxAge":4,"enrollmentInfo":567,"targetDuration":4,"studyType":111,"phases":4,"briefSummary":569,"conditions":570,"keywords":573,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":582,"lastUpdatePostDateStruct":583,"startDateStruct":584,"completionDateStruct":586,"leadSponsor":588,"locationsCount":99},"100449349","frame-study-frailty-related-ankle-fracture-management-and-evaluation-100449349","NCT05131321","FRAME Study (Frailty-Related Ankle Fracture Management and Evaluation)","FRAME Study (Frailty-Related Ankle Fracture Management and Evaluation): Retrograde Nailing Versus Open Reduction and Internal Fixation for Unstable Fractures Around the Ankle in the Frail Elderly - A Two-Part Prospective, Randomized, Multi-Center Clinical Trial","FRAME","Patient Inclusion Criteria - Both Parts:\n\n(i) Age ≥ 60 years (ii) One or more of the following:\n\n* Severe soft tissue compromise\n* Significant co-morbidities (vascular disease + chronic trophic changes, diabetes + neuropathy, chronic renal failure, morbid obesity (BMI\\> 40))\n* Frailty as defined by a Dalhousie Clinical Frailty Scale score ≥4\n\nPart 1 Specific Inclusion Criteria:\n\n(i) Isolated fracture (within 4 weeks of injury): an AO\u002FOTA type 43C2 or C3 tibial pilon fracture or severe ankle fracture (fracture-dislocation, severe joint impaction, severe trimalleolar)\n\nPart 2 Specific Inclusion Criteria (i) Isolated fracture (within 4 weeks of injury): an AO\u002FOTA type 44B2, B3, C1 or C2 ankle fracture\n\nPatient Exclusion Criteria - Both Parts:\n\n(i) Presence of vascular injury or pathologic fracture; (ii) Previous tibia pilon fracture or retained hardware in affected limb; (iii) Refusal to participate; (iv) Inability to obtain informed consent due to language barrier","40 Years",{"count":568,"type":21},172,"This will be a multi-centre randomized controlled trial, with London Health Sciences Centre (LHSC) as the lead site. Elderly patients with complex ankle fractures who meet the inclusion criteria and provide consent will be randomized (through a web-based randomization system) to one of the two treatment arms. One group (Group A) will receive primary ankle fusion, and the second group (Group B) will receive primary ankle open reduction and internal fixation (ORIF). Patient important outcomes will be compared at one year post injury\n\nThe Investigators have amended the study to include a second part for patients with less complicated but still unstable ankle fractures. In this part, patients will be randomly assigned to receive either a procedure called ORIF or another one called retrograde intramedullary fibular nailing.",[571,572],"Ankle Fractures","Pilon Fracture",[574,575,576,577,578,579,580,581],"Complex ankle fracture","Pilon fracture","Primary Ankle Arthrodesis","Fragility fracture","Elderly","Open reduction","Internal fixation","AO\u002FOTA type 44B2, B3, C1 or C2 ankle fracture","2026-01-26",{"date":550,"type":32},{"date":585,"type":32},"2022-04-21",{"date":587,"type":21},"2028-12",{"name":38,"class":39},{"id":590,"slug":591,"hasResults":12,"nctId":592,"briefTitle":593,"officialTitle":594,"acronym":4,"eligibilityCriteria":595,"healthyVolunteers":12,"sex":17,"minAge":596,"maxAge":597,"enrollmentInfo":598,"targetDuration":4,"studyType":111,"phases":4,"briefSummary":599,"conditions":600,"keywords":602,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":609,"lastUpdatePostDateStruct":610,"startDateStruct":612,"completionDateStruct":614,"leadSponsor":616,"locationsCount":99},"100604012","the-fecal-microbiome-transplant-fmt-study-for-anorexia-nervosa-100604012","NCT07143981","The Fecal Microbiome Transplant (FMT) Study for Anorexia Nervosa","Fecal Microbiome Transplant to Normalize Gut Microbiota, Metabolomics, Immunology, Cognitive and Affective Processing in Patients Suffering From Anorexia Nervosa","Inclusion Criteria:\n\n* meet DSM 5 criteria for AN, restricting type, moderate or higher severity, as indicated by a BMI\\\u003C17\n* Participants must we willing and able to swallow FMT capsules without vomiting\n* Able to read and understand conversational English\n\nExclusion Criteria:\n\n1. Medical or psychiatric instability needing hospitalization\n2. Patients with AN binge\u002Fpurge type\n3. Use of antibiotics or probiotics in the month prior to treatment\n4. Regular oral steroid use, or potent topical steroid use on large sections of skin\n5. Chronic immune compromise and chronic illness affecting the intestinal tract or metabolic health\n6. Pregnancy or intended pregnancy over the time of study\n7. Patients enrolled in any treatment program that involves refeeding","16 Years","35 Years",{"count":327,"type":21},"Anorexia Nervosa (AN) is a severe, debilitating and potentially life threatening illness that is difficult to treat. A cardinal symptom of AN is the mistaken belief on the part of the individuals that they are overweight and must continue to restrict intake. This fixed false belief is a detrimental factor to recovery. It is known that AN involves disturbance in the gut microbiome (GM; the microbes that live in the lower intestinal tract). The GM also affects how one thinks and makes food choices - there appears to be a direct link between the GM and how the brain functions. This connection is thought to occur through chemical processes that convey information from the gut to the brain. It is known that fecal microbiome transplant (FMT) has been useful in treating several illnesses, including several mental illnesses. The investigators intend to deliver FMT to individuals with AN to determine the extent to which this modifies their GM, their biochemistry, their thinking processes and their moods and emotions. The investigators believe this will illuminate important aspects of AN that keep the illness in place, and that this will uncover useful approaches to better treat it.",[601],"Anorexia Nervosa",[603,604,605,606,607,608],"Microbiome","Fecal transplant","Gut microbiome","Gut brain axis","Mental health","Eating Disorders","2026-01-21",{"date":611,"type":32},"2026-01-23",{"date":613,"type":21},"2026-01-15",{"date":615,"type":21},"2027-08-31",{"name":38,"class":39},{"id":618,"slug":619,"hasResults":12,"nctId":620,"briefTitle":621,"officialTitle":622,"acronym":4,"eligibilityCriteria":623,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":624,"targetDuration":4,"studyType":22,"phases":626,"briefSummary":627,"conditions":628,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":630,"lastUpdatePostDateStruct":631,"startDateStruct":633,"completionDateStruct":634,"leadSponsor":636,"locationsCount":4},"100617327","meta-glasses-for-low-vision-100617327","NCT07317180","Meta Glasses for Low Vision","The Use of Meta AI Glasses With Be My Eyes Network to Improve Mobility in Patients With Low Vision","Inclusion Criteria:\n\n1. Confirmed diagnosis of glaucoma, retinal dystrophy, or another condition associated with legal blindness.\n2. Presence of documented irreversible vision loss\n3. No surgical or laser procedures in the last 6 months\n4. Visual field worse than 12db or poor visual acuity 20\u002F400 or worse\n\nExclusion Criteria:\n\n1. Has no access to telephone\n2. Unable to speak English\n3. Has previously received comprehensive low vision services\n\n5\\. Has history of stroke with aphasia 6. Has other health condition that would preclude follow-up (e.g., significant malignancy or life-threatening disease) 7. Is unable or unwilling to attend clinic visits required for the study 8. Reports significant loss of vision since last eye exam",{"count":625,"type":21},50,[24],"Visual impairment, particularly from glaucoma and retinal dystrophies, significantly hinders mobility and increases the risk of falls, leading to decreased independence and mental health challenges. Current low-vision assistive technologies primarily focus on near-task magnification for reading, leaving a critical gap in tools designed to assist with real-world navigation and peripheral vision loss. To address this, the proposed research evaluates Meta AI glasses, which offer real-time scene narration and object recognition, integrated with the Be My Eyes network. The study hypothesizes that this wearable AI technology will improve ambulation, orientation, and overall quality of life for patients, providing a functional solution for mobility that traditional devices lack.",[629],"Irreversible Vision Loss","2025-12-19",{"date":632,"type":32},"2026-01-05",{"date":432,"type":21},{"date":635,"type":21},"2027-07-01",{"name":38,"class":39},""]